# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Mary McLeod Bethune (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML043-SYN-TD
- Date: 1948-05-04
- Fictional facility: St. Posthumous Health Center
- Fictional author: Viola Harrington-Mbeki, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Six-week asthma review. **S**

## History of present illness

Mrs. Bethune returns six weeks after starting budesonide-formoterol. Her nights are better, waking once a week, but she is still breathless on stairs some days and has used the inhaler as a reliever three or four times a week. The dose counter shows she has taken about 70 percent of her maintenance doses: she sometimes forgets the evening dose when she is working late. She saw the ear, nose and throat specialist two weeks ago; nasal endoscopy showed chronic rhinosinusitis without polyps, and her nose is clearer on the steroid spray. Heartburn has gone on omeprazole. Home blood pressure averages 132/78. She has had no ankle swelling on amlodipine and no muscle aches on atorvastatin. She has had no thoughts of self-harm. **S**

| Element | Detail |
|---|---|
| Control | Asthma Control Test 18; night waking once a week; reliever three or four times a week |
| Adherence | About 70 percent of maintenance doses by the dose counter |
| Ear, nose and throat | Chronic rhinosinusitis without nasal polyps on endoscopy |
| Home blood pressure | Average 132/78 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Night waking once a week; breathless on stairs some days |
| Ears, nose, mouth, and throat | Positive | Nose clearer; smell a little better; no hoarseness or thrush |
| Gastrointestinal | Negative | No heartburn on omeprazole |
| Cardiovascular | Negative | No ankle swelling, chest pain or palpitations |
| Musculoskeletal | Negative | No muscle aches |

5 systems reviewed. **S**

## Current medications

- Budesonide-formoterol 160/4.5 mcg inhaler as maintenance and reliever (GINA track 1, step 3): one inhalation twice daily and one inhalation as needed for symptoms, no more than 12 inhalations a day **S**
- Fluticasone propionate 50 mcg/actuation nasal spray, two sprays in each nostril once daily, aimed away from the septum **S**
- Sodium chloride 0.65% nasal spray, two sprays in each nostril up to four times daily before the steroid spray **S**
- Amlodipine 5 mg oral tablet, one tablet daily **S**
- Atorvastatin 20 mg oral tablet, one tablet daily **S**
- Omeprazole 20 mg delayed-release capsule, one capsule daily 30 minutes before breakfast for eight weeks **S**

## Allergies

- No known allergy **S**

## Objective

BP 134/80 mmHg; pulse 76 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 87 kg; BMI 32.7 kg/m². All vital signs are synthetic.

Asthma Control Test: 18; Potassium: 4.2 mmol/L; Creatinine: 0.94 mg/dL; eGFR (CKD-EPI 1943): 64 mL/min/1.73 m²; Total cholesterol: 170 mg/dL; HDL cholesterol: 57 mg/dL; Triglycerides: 126 mg/dL; LDL cholesterol: 88 mg/dL. All results are synthetic.

## Change since baseline

- Asthma Control Test: 13 at baseline, 18 at this visit **S**
- Potassium: 4.1 mmol/L at baseline, 4.2 mmol/L at this visit **S**
- Creatinine: 0.92 mg/dL at baseline, 0.94 mg/dL at this visit **S**
- eGFR (CKD-EPI 1943): 66 mL/min/1.73 m² at baseline, 64 mL/min/1.73 m² at this visit **S**
- Total cholesterol: 228 mg/dL (high) at baseline, 170 mg/dL at this visit **S**
- HDL cholesterol: 56 mg/dL at baseline, 57 mg/dL at this visit **S**
- Triglycerides: 140 mg/dL at baseline, 126 mg/dL at this visit **S**
- LDL cholesterol: 144 mg/dL (high) at baseline, 88 mg/dL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 87.0 kg; blood pressure 134/80, pulse 76; oxygen saturation 97 percent |
| Mouth | No thrush |
| Respiratory | A few expiratory wheezes on forced expiration |
| Extremities | No ankle edema |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Asthma on low-dose ICS-formoterol maintenance and reliever** (J45.40). Better but not yet well controlled (Asthma Control Test 18). Her technique has three errors and she misses about a third of the maintenance doses, so the treatment has not had a fair trial: GINA advises correcting technique and adherence before stepping up, and that is what we did. **S**
   - Retrained with a spacer and checked by teach-back.
   - Evening dose linked to her nightly reading, with a phone reminder.
   - Same dose; review after any change, or at the next planned visit.
   - Peak flow diary for two weeks to set her personal best.
2. **Chronic rhinosinusitis without nasal polyps** (J32.9). Confirmed on nasal endoscopy; improving on the steroid spray. **S**
   - Continue fluticasone and saline.
3. **Chronic nasal symptoms** (R09.81). Explained by chronic rhinosinusitis; superseded. **S**
   - Problem resolved.
4. **Hypertensive heart disease without heart failure** (I11.9). Clinic 134/80, home 132/78 on amlodipine; potassium 4.2 and eGFR 64, stable. Near but not yet at target. **S**
   - Continue amlodipine 5 mg; recheck home readings in a month and add a low-dose thiazide-like diuretic if still above 130/80.
5. **Hyperlipidemia** (E78.5). LDL 88 mg/dL, down 39 percent on atorvastatin; no muscle symptoms. **S**
   - Continue atorvastatin 20 mg.
6. **Gastro-esophageal reflux** (K21.9). Heartburn gone. **S**
   - Finish the eight weeks of omeprazole in two weeks, then stop and use the meal-timing measures.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Asthma Control Test, symptoms, night waking and reliever use | Every visit | Completed today | Asthma Control Test 18; night waking once a week; reliever three or four times a week |
| Examination | Inhaler technique with her own inhaler, and adherence | Every visit; before any step-up | Completed today | Three errors (not shaking, fast breath in, no breath-hold) corrected with a spacer; adherence about 70 percent by dose counter |
| Self-management | Exacerbation history (oral corticosteroid courses, emergency visits, admissions) | Every visit | Completed today | None since the last visit |
| Self-management | Step-up or step-down assessment (GINA track 1) | Every visit | Completed today | No step-up until technique and adherence are corrected |
| Self-management | Written asthma action plan | Every visit and after every exacerbation | Completed today | Reviewed; peak flow diary to set her personal best |
| Self-management | Triggers, exposures and smoking or vaping | Every visit | Completed today | Dust mite covers in place; avoids perfume at meetings where she can |
| Imaging | Spirometry after stabilization | Three to six months after starting treatment | Due | Planned for the next visit |
| Examination | Comorbidities | At diagnosis and yearly | Completed today | Chronic rhinosinusitis confirmed; reflux settled |
| Examination | Blood pressure in clinic and at home | Every visit; home readings at diagnosis and after changes | Completed today | Clinic 134/80; home average 132/78 |
| Laboratory | Potassium and kidney function after starting treatment | After starting or changing antihypertensive treatment | Completed today | Potassium 4.2, creatinine 0.94, eGFR 64 |
| Laboratory | Lipid panel after starting a statin | Four to twelve weeks after starting, then yearly | Completed today | Total cholesterol 170, HDL 57, triglycerides 126, LDL 88 |

## Goal progress

- A confirmed diagnosis within three weeks: spirometry with bronchodilator response, FeNO and an echocardiogram, with the pulmonology consultation. Outcome by 1948-03-23: Asthma confirmed by a 21 percent, 270 mL bronchodilator response and FeNO 46 ppb; heart failure excluded; hypertensive heart disease found, two weeks after the first visit. **S**
- Asthma Control Test 20 or more, no night waking, and travel to Washington without breathlessness. In progress; target 1948-07-27. **S**
- Correct inhaler technique with her own inhaler at every visit, and a written asthma action plan she can use. Outcome by 1948-05-04: Technique corrected with a spacer at six weeks; action plan written at diagnosis and used during the exacerbation. **S**
- Blood pressure below 130/80 at home and in clinic. In progress; target 1948-07-27. **S**
- No exacerbation needing oral corticosteroids. In progress; target 1948-07-27. **S**

## Guideline basis

- CMID: Clinical Monitoring Intelligence Database, asthma and hypertension monographs (2026), Aether Forge
- Global Strategy for Asthma Management and Prevention, 2025 update (2025), Global Initiative for Asthma
- 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020), National Heart, Lung, and Blood Institute (J Allergy Clin Immunol 2020;146(6):1217-1270)
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (J Am Coll Cardiol 2025)

## Follow-up

- Next planned review in about three months, sooner for any change. Call the clinic in the yellow zone of her action plan. **S**
- Next scheduled visit 1948-07-27: review six weeks after an exacerbation: control, repeat spirometry and FeNO, biologic assessment, blood pressure and the post-exacerbation plan. **S**
